Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$27,000.00
Imaging Monoacylglycerol Lipase: Positron Emission Tomography Study with [18F]MAGL-2102
FY 2024-25
Summary
The proposed research aims to validate [18F]MAGL-2102, a novel radiopharmaceutical tracer designed to target monoacylglycerol lipase (MAGL). MAGL is a critical enzyme in the endocannabinoid system responsible for metabolizing the primary ligand of cannabinoid receptor 1. MAGL inhibitors have demonstrated therapeutic potential with effects such as analgesic, hypo-motility, hypothermic, and anxiolytic effects, highlighting their value as intervention targets in neuropsychiatric disorders. Accurate measurement of MAGL in the brain has historically been challenging due to difficulties in developing tracers with high uptake and binding; however, the novel tracer [18F]MAGL-2102 has demonstrated promising results in preclinical studies. This study represents the first-in-human evaluation of [18F]MAGL-2102, aiming to assess its safety, binding profile, biodistribution, and pharmacokinetics in healthy controls. The study also seeks to quantify radiation dose distribution across body organs through whole-body dosimetry and evaluate the tracer's reliability over time using a test-retest design. Ten healthy volunteers (5 males, 5 females, aged 19–65) will undergo medical and psychological screening. Each participant will receive an injection of 185 MBq (±10%) [18F]MAGL-2102 for a 120-minute brain PET/CT scan, followed by a repeat scan one month later to assess test-retest reliability. Whole-body scans will use the same dose, with CT and dynamic 3D imaging from head to mid-thigh over 120 minutes. The successful validation of [18F]MAGL-2102 could provide in vivo quantification of MAGL in the brain, significantly advancing our understanding of its role and function and ultimately supporting the development of targeted therapeutic interventions for neuropsychiatric disorders.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
539222
Name
Jebanesan Bertina
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Imaging Monoacylglycerol Lipase: Positron Emission Tomography Study with [18F]MAGL-2102
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Endocannabinoid System; Molecular Imaging; Monoacylglycerol Lipase (Magl); Positron Emission Tomography (Pet); Radiopharmaceuticals; Tracer Validation
Abstract
The proposed research aims to validate [18F]MAGL-2102, a novel radiopharmaceutical tracer designed to target monoacylglycerol lipase (MAGL). MAGL is a critical enzyme in the endocannabinoid system responsible for metabolizing the primary ligand of cannabinoid receptor 1. MAGL inhibitors have demonstrated therapeutic potential with effects such as analgesic, hypo-motility, hypothermic, and anxiolytic effects, highlighting their value as intervention targets in neuropsychiatric disorders. Accurate measurement of MAGL in the brain has historically been challenging due to difficulties in developing tracers with high uptake and binding; however, the novel tracer [18F]MAGL-2102 has demonstrated promising results in preclinical studies. This study represents the first-in-human evaluation of [18F]MAGL-2102, aiming to assess its safety, binding profile, biodistribution, and pharmacokinetics in healthy controls. The study also seeks to quantify radiation dose distribution across body organs through whole-body dosimetry and evaluate the tracer's reliability over time using a test-retest design. Ten healthy volunteers (5 males, 5 females, aged 19–65) will undergo medical and psychological screening. Each participant will receive an injection of 185 MBq (±10%) [18F]MAGL-2102 for a 120-minute brain PET/CT scan, followed by a repeat scan one month later to assess test-retest reliability. Whole-body scans will use the same dose, with CT and dynamic 3D imaging from head to mid-thigh over 120 minutes. The successful validation of [18F]MAGL-2102 could provide in vivo quantification of MAGL in the brain, significantly advancing our understanding of its role and function and ultimately supporting the development of targeted therapeutic interventions for neuropsychiatric disorders.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jebanesan, Bertina
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~